指南与共识慢性肾脏病肾血管病与高血压血液净化与透析

ASN肾脏健康指南:心血管-肾脏-代谢综合征执行摘要

Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome.
指南 / 共识 · J Am Soc Nephrol · 2026-09-02

该指南由ASN发布,旨在推动肾内科参与CKM综合征管理,强调肾病在CKM中的核心作用并提出CKD特异性建议。指南推荐使用PREVENT方程评估心血管风险,以RAS抑制剂和SGLT2抑制剂为基础治疗,并按患者风险加用GLP-1疗法或非甾体MRA。

要点

  • CKD患者应常规评估心血管风险、代谢健康和肾功能。
  • PREVENT方程应联合肾脏结局预测因素用于风险咨询。
  • RAS抑制剂和SGLT2抑制剂是CKD预防心肾终点的基石治疗。

核心结论

  • CKM框架鼓励常规评估心血管风险、代谢健康和肾功能,肾脏病在CKM综合征中居核心地位。

研究设计与样本

  • ASN肾脏健康指南,基于近期AHA/ACC/ADA/ASN首部CKM综合征指南制定。

主要发现

  • CKD常合并心血管和代谢疾病,定期评估应涵盖各疾病状态的筛查与管理。
  • RAS抑制剂和SGLT2抑制剂是CKD预防心血管和肾脏终点的 foundational 治疗。
  • GLP-1基础疗法和非甾体MRA可根据患者心血管和代谢风险个体化加用。

关键数值与推荐

  • CKD患者应使用心血管风险方程指导预防治疗并促进护理协调。
  • PREVENT方程应联合肾脏结局预测因素用于常规患者咨询和风险评估。
  • 生活方式干预包括规律体力活动、避免烟草、健康饮食和睡眠模式。
  • CKM治疗可同时或快速序贯启动,但须避免治疗惰性。
  • 心血管疾病缓解还应包括一级和二级预防的血脂管理。

临床怎么用

  • 肾内科团队应主导CKD患者CKM综合征的诊断、治疗及多学科整体管理。
  • 根据个体心血管和代谢风险谱,在 foundational 治疗上加用GLP-1疗法或非甾体MRA。
  • 对肾小球肾炎、肾移植、透析、儿科、老年及衰弱人群,筛查诊断仍关键,治疗可共享决策使用。

局限性

  • 支持CKM治疗在肾小球肾炎、肾移植、维持性透析、儿科、老年和衰弱人群中获益的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The cardiovascular‑kidney‑metabolic framework encourages routine assessment of cardiovascular risk, metabolic health, and kidney function. Cardiovascular risk equations should be used in patients with CKD to direct preventive therapies and promote coordination of care to optimize outcomes. Comprehensive therapy building upon foundational CKD management is essential to minimize treatment gaps and improve cardiovascular‑kidney‑metabolic outcomes. UNLABELLED: The recent release of the inaugural AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome calls for health care professionals across disciplines to broaden their practice to include the full spectrum of these interconnected disease states. This ASN Kidney Health Guidance aims to unite the nephrology community in this effort, highlighting the central role kidney disease plays in CKM syndrome and providing CKD-specific considerations. CKD is often complicated by comorbid cardiovascular and metabolic diseases, and regular evaluation of patients should include screening and management across disease states. The Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equation should be integrated along with kidney outcome predictors for routine patient counseling and risk assessment. Lifestyle modifications, including regular physical activity, avoidance of tobacco products, and adoption of a healthy diet and sleep patterns, underpin CKM management. Both renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors are foundational therapies in CKD for the prevention of cardiovascular and kidney end points, and glucagon-like peptide-1-based therapies and nonsteroidal mineralocorticoid receptor antagonists may be added according to an individual patient's cardiovascular and metabolic risk profile. CKM therapies may be initiated simultaneously or in rapid sequence according to shared decision making, but therapeutic inertia must be avoided. Cardiovascular disease mitigation should also include lipid management for primary and secondary prevention. Evidence supporting the benefits of CKM treatments in people with glomerulonephritis, those with kidney transplant, those on dialysis with kidney failure treated with maintenance dialysis, pediatric populations, older adults, and those with frailty is limited. However, screening and diagnosis of CKM syndrome are critical, and these cardiokidney protective therapies may be used with shared decision making. Diabetes and obesity are extremely common in people living with kidney disease; both are major contributors to CKD progression. CKD poses a major risk of cardiovascular morbidity and mortality. Hence, nephrology team members should play a vital role in the diagnosis, treatment, and implementation of a holistic and multidisciplinary approach for the well-being of patients with kidney diseases. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_09_02_KTS_September2026.mp3.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Navaneethan SD, Rifkin B, Mottl AK, et al. Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome. J Am Soc Nephrol. 2026. PMID: 42684404. doi:10.1681/ASN.0000001230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。